5.6 C
New York
Thursday, March 5, 2026

This Key Gene-Editing Test Is Dragging Down All CRISPR Stocks

Intellia Therapeutics (NTLA) said early Friday it found a way to knock out the gene responsible for a rare and deadly swelling disorder — but NTLA …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

149,450FansLike
396,312FollowersFollow
2,650SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x